STAT+: Amgen, Arrakis Therapeutics partner to develop oral drugs that eliminate troublesome RNA

Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively destroy RNA molecules that turn genetic instructions into disease-causing proteins.

Called “targeted RNA degraders,” this emerging technology will go after targets that traditional drug-development methods can’t reach.

Continue to STAT+ to read the full story…